All In Biotech

Drug Trial Radar · NCT07038824

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 30, 2025

Primary completion

Mar 1, 2029

Study completion Mar 1, 2029

Sponsor

Lead sponsor
Entrada Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 4 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENTR-601-45, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-45 and placebo are both called study treatments. The study has 2 parts: Part A: to evaluate if ENTR-601-45 is safe and to determine the best dose of ENTR-601-45 for Part B. Part B: to further evaluate the effect and safety of ENTR-601-45 at the dose determined in Part A. Participants will be able to roll into an open-label treatment period during which the safety and efficacy of extended dosing will be evaluated. Participants will: * Receive study treatment in the form of multiple intravenous (IV) infusions (slow injection) into a vein over the course of several weeks in Part A and in Part B * Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, muscle biopsies and exercise tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a result of the study drug. Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

  • ENTR-601-45Drug

    intravenous infusion

  • ENTR-601-45 - matching placeboDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period).Time frame: From baseline through End of Study (up to 62 weeks).

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • University Hospital Gent

    Ghent, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Régional de la Citadelle

    Liège, Belgium · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy · Recruiting

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands · Recruiting

  • Stichting Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Sant Joan de Deu

    Barcelona, Spain · Recruiting

  • Leeds General Infirmary

    Leeds, United Kingdom · Recruiting

  • Alder Hey Children's NHS Foundation Trust

    Liverpool, United Kingdom · Recruiting

  • Great Ormond Street Hospital for Children

    London, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Not yet recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.